Robert Carnahan

Five exceptional Vanderbilt faculty members have been named 2025 Master Innovators for their extraordinary contributions to translating research into commercial applications that have significant societal impact. The 2025 honorees represent diverse fields from infectious disease therapeutics to neuroscience drug discovery and biomedical engineering.  Read More

Infectious diseases pose a significant global health challenge, accounting for a substantial proportion of deaths worldwide, according to recent data from the World Health Organization. Vanderbilt’s Life Science Showcase: Advancing Innovation in Infectious Diseases held on July 18 emphasized the vital importance of advancing research and innovation to combat these persistent threats. Read More

Vanderbilt was part of a multi-center team that resurrected a “dead antibody” to reveal the mysteries of cytochrome c, a versatile protein that is an essential part of the cell’s energy-generating capacity, and of life itself. Read More

Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19. Read More

After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio. Read More

From the front lines of patient care to collaborating with scientists across the globe searching for treatments and vaccines, Vanderbilt University Medical Center and Vanderbilt University researchers have been working for months to combat the COVID-19 pandemic. Read More

Scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis are racing to develop — in a mere 90 days — a protective antibody-based treatment that can stop the spread of the Zika virus. Read More